We’re excited to announce the near doubling of our ISO-certified manufacturing facility in northeast England. The increased laboratory space includes a major investment in new automation for Next Generation Sequencing (NGS), expression and purification (HPLC) to enhance recombinant antibody production workflows. The additional space and equipment will enable us to better service customers and accelerate the expansion of our recombinant antibody portfolio.
“The increased space and automation is a direct result of the continued growth of our company and underlines our commitment to our clients and to advancing recombinant antibody technology,” said Dr. Ed Horton, Chief Commercial Officer of Absolute Antibody. “We are excited to leverage our increased production capacity and additional automation capabilities to serve new and existing customers more efficiently and respond to the growing demand for recombinant antibodies across a variety of applications.”
Our upgraded space includes additional manufacturing lines and state-of-the-art robotics to increase efficiency and enable the completion of larger and higher volume projects. The new labs will also accommodate additional scientific staff members to support company growth, while still providing the highest quality antibody services and products.
Antibody Engineering and Therapeutics – Booth #402
4-9th December 2022
San Diego, California